Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

ClinicalTrials.gov ID: NCT02839330

Public ClinicalTrials.gov record NCT02839330. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Observer-Blind, Multi-center, Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase 3 study evaluates the safety, immunogenicity and lot-to lot consistency of 3 lots of aH5N1c vaccine for pandemic avian influenza, in approximately 2394 healthy adults ≥18 years of age receiving the vaccine and 797 healthy adults receiving placebo. Subjects were randomized in a 3:1 ratio to receive either aH5N1c vaccine or saline placebo. Enrollment was stratified by age: 18 to \<65 years of age and ≥65 years of age, to allow adequate safety assessment of the entire age spectrum.

Study identification

NCT ID
NCT02839330
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Seqirus
Industry
Enrollment
3,196 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 10, 2016
Primary completion
Oct 3, 2017
Completion
Oct 3, 2017
Last update posted
Dec 5, 2024

2016 – 2017

United States locations

U.S. sites
26
U.S. states
15
U.S. cities
23
Facility City State ZIP Site status
Optimal Research, LLC Huntsville Alabama 35802
Radiant Research Chandler Arizona 85224
Clinical Research Consortium Arizona Tempe Arizona 85283
Optimal Research Site San Diego California 92108
California Research Foundation San Diego California 92123
Clinical Research Consulting, LLC Milford Connecticut 06460
Innovative Research of West Florida, Inc. Clearwater Florida 33756
Optimal Research, LLC Melbourne Florida 32934
Great Lakes Clinical Trials LLC Chicago Illinois 60640
Optimal Research Peoria Illinois 61614
Heartland Research Associates Wichita Kansas 67207
Optimal Research, LLC Rockville Maryland 20850
The Center for Pharmaceutical Research Kansas City Missouri 64114
Sundance Clinical Research, LLC St Louis Missouri 63141
RCR/United Medical Associates, PC Binghamton New York 13901
Rochester Clinical Research, Inc Rochester New York 14609
PMG Research of Raleigh Raleigh North Carolina 60640
PMG Research of Winston-Salem Winston-Salem North Carolina 27609
Aventiv Research Columbus Ohio 43213
Medical Research South Charleston South Carolina 29407
Spartanburg Medical Research Spartanburg South Carolina 29303
Biogenics Research Institute San Antonio Texas 78229
J. Lewis Research Inc.-Foothill Family Clinic Salt Lake City Utah 84109
J. Lewis Research, Inc. / FirstMed East Salt Lake City Utah 84121
J. Lewis Research, Inc/Foothill Family Clinic South Salt Lake City Utah 84121
J. Lewis Research, Inc/Jordan River Family Medicine South Jordan Utah 84095

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02839330, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 5, 2024 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02839330 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →